No Data
No Data
Insider Sale: Chief Technology Officer of $RNAC (RNAC) Sells 2,901 Shares
Cartesian Therapeutics Insider Sold Shares Worth $345,134, According to a Recent SEC Filing
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Cartesian Therapeutics (RNAC) and Terns Pharmaceuticals (TERN)
Promising Clinical Developments and Pivotal Trials Position Cartesian Therapeutics for Long-term Success
H.C. Wainwright Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Raises Target Price to $45
Express News | HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Raises Price Target to $45